Erratum to “Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer” [Journal of Cancer Therapy, 6, 1083-1092]

Ruixia Guo^*, Xinyan Wang, Ruifang Zhang, Huirong Shi, Yuhuan Qiao, Wenjing Yun, Xin Ge, Yan Lin, Jia Lei

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

DOI: 10.4236/jct.2021.1210048                

Abstract

The original online version of this article (Guo, R., Wang, X., Zhang, R., Shi, H., Qiao, Y., Yun, W., Ge, X., Lin, Y. and Lei, J. (2015) Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer. Journal of Cancer Therapy, 6, 1083-1092. https://doi.org/10.4236/jct.2015.612118) was published in November 2015. The authors wish to correct the following error.

Keywords

Erratum

The original online version of this article (Guo, R., Wang, X., Zhang, R., Shi, H., Qiao, Y., Yun, W., Ge, X., Lin, Y. and Lei, J. (2015) Response of Subcutaneous Xenografts of Endometrial Cancer in Nude Mice to Inhibitors of Phosphatidylinositol 3-Kinase/Akt and Mitogen-Activated Protein Kinase (MAPK) Pathways: An Effective Therapeutic Strategy for Endometrial Cancer. Journal of Cancer Therapy, 6, 1083-1092. https://doi.org/10.4236/jct.2015.612118) was published in November 2015. The authors wish to correct the following error.

The original version of Figure 3 is inappropriate. We replace Figure 3 with the following figure:

Figure 3. H/E staining (×40) of xenograft tumors. Representative H/E-stained sections of Ishikawa (A)-(D) and HEC-1A cell (E)-(H) xenografts in different groups. Compared with the controls, the number of tumor cells decreased and the number of nuclei decreased by varying degrees in groups treated with PD98059, LY294002 or a combination of both.

Conflicts of Interest

The authors declare no conflicts of interest.

References